---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-099029"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:58:03.783036+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TransCode completes Phase 1a of TTX-MC138; 44% stable disease rate, moves to Phase 2a

## Summary
- 16 patients treated across 4 dose levels; no dose-limiting toxicities or significant safety events observed.
- Median treatment duration of 4 months (range 2–12); three patients remain on trial.
- 44% (7/16) achieved stable disease lasting ≥4 months per RECIST; one thyroid cancer patient had undetectable thyroglobulin.
- Recommended Phase 2 dose established; company plans to initiate Phase 2a efficacy trial.
- PK profile shows predictable exposure; pharmacodynamic effects consistent with preclinical models and prior Phase 0.

## SEC filing metadata
- accession: 0001104659-25-099029
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465925099029/0001104659-25-099029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465925099029/tm2528668d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-099029
- JSON: https://secwatch.observer/filing/0001104659-25-099029.json
- Plain text: https://secwatch.observer/filing/0001104659-25-099029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.